Literature DB >> 10694241

A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin.

O A al-Swayeh1, R H Clifford, P del Soldato, P K Moore.   

Abstract

1. Nitroaspirin (2.5 - 50 mg kg(-1), i.p. or 2.5 - 100 mg kg(-1), p.o.) and aspirin (2.5 - 100 mg kg(-1), i.p. or p.o.) exhibit anti-inflammatory activity in the carrageenan-induced hindpaw oedema model in the rat. When administered i.p., nitroaspirin was a more effective anti-oedema agent than aspirin particularly in the 'early' phase (i.e. up to 60 min) of the response. The ED(50) values for nitroaspirin and aspirin as inhibitors of the 'late' phase response (measured at 180 min) were 64.3 micromol kg(-1) and >555 micromol kg(-1), respectively. When administered p.o., neither nitroaspirin nor aspirin exhibited significant anti-inflammatory activity in the 'early' phase and were of similar potency in the 'late' phase. Thus, at the highest dose used (100 mg kg(-1), 360 min) orally administered nitroaspirin (aspirin in parenthesis) inhibited oedema formation by 46.9+/-1.6% (47.2+/-3.8%, both n=6, P<0.05). 2. Nitroaspirin and aspirin (25 - 200 mg kg(-1), p.o.) caused dose-related inhibition of the hyperalgesia to mechanical stimulation following intraplantar injection of carrageenan in the rat. ED(50) values were 365 micromol kg(-1) and 784 micromol kg(-1), respectively. Neither drug influenced the threshold for mechanical stimulation in the contralateral (i.e. untreated) hindpaw. 3. Nitroaspirin and aspirin (2.5 - 100 mg kg(-1), p.o.) caused dose-related inhibition of acetic acid induced abdominal constrictions in the mouse (ED(50) values of 154.7 micromol kg(-1) and 242.8 micromol kg(-1), respectively). 4. Nitroaspirin and aspirin (>200 mg kg(-1), p.o.) reduced the 'late' phase (but not the 'early' phase) of the formalin-induced hindpaw licking assay in the mouse. Similarly, nitroaspirin and aspirin (>50 mg kg(-1), p.o.) prolonged tail withdrawal latency following application of a noxious heat stimulus in the mouse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694241      PMCID: PMC1571848          DOI: 10.1038/sj.bjp.0703064

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

Review 1.  NO-aspirins: a class of new anti-inflammatory and antithrombotic agents.

Authors:  P del Soldato; R Sorrentino; A Pinto
Journal:  Trends Pharmacol Sci       Date:  1999-08       Impact factor: 14.819

2.  In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016.

Authors:  J L Wallace; M N Muscara; W McKnight; M Dicay; P Del Soldato; G Cirino
Journal:  Thromb Res       Date:  1999-01-01       Impact factor: 3.944

3.  Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats.

Authors:  S Fiorucci; E Antonelli; L Santucci; O Morelli; M Miglietti; B Federici; R Mannucci; P Del Soldato; A Morelli
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

4.  Pharmacological analysis of cyclooxygenase-1 in inflammation.

Authors:  C J Smith; Y Zhang; C M Koboldt; J Muhammad; B S Zweifel; A Shaffer; J J Talley; J L Masferrer; K Seibert; P C Isakson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

5.  Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine.

Authors:  M Di Rosa; J P Giroud; D A Willoughby
Journal:  J Pathol       Date:  1971-05       Impact factor: 7.996

6.  Biphasic development of carrageenin edema in rats.

Authors:  R Vinegar; W Schreiber; R Hugo
Journal:  J Pharmacol Exp Ther       Date:  1969-03       Impact factor: 4.030

7.  Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.

Authors:  E W Ehrich; A Dallob; I De Lepeleire; A Van Hecken; D Riendeau; W Yuan; A Porras; J Wittreich; J R Seibold; P De Schepper; D R Mehlisch; B J Gertz
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

Review 8.  Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.

Authors:  H B Fung; H L Kirschenbaum
Journal:  Clin Ther       Date:  1999-07       Impact factor: 3.393

9.  Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats.

Authors:  J L Wallace; N Vergnolle; M N Muscará; S Asfaha; K Chapman; W McKnight; P Del Soldato; A Morelli; S Fiorucci
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

10.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.

Authors:  M J Yin; Y Yamamoto; R B Gaynor
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

View more
  13 in total

1.  NCX-701 (nitroparacetamol) is an effective antinociceptive agent in rat withdrawal reflexes and wind-up.

Authors:  E Alfonso Romero-Sandoval; Javier Mazario; David Howat; Juan F Herrero
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide?

Authors:  M Y Ali; C Y Ping; Y-Yp Mok; L Ling; M Whiteman; M Bhatia; P K Moore
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

3.  Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats.

Authors:  M N Muscará; F Lovren; W McKnight; M Dicay; P del Soldato ; C R Triggle; J L Wallace
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs.

Authors:  J Keeble; O A Al-Swayeh; P K Moore
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

5.  Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity.

Authors:  O A al-Swayeh; L E Futter; R H Clifford; P K Moore
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  Oral bioavailability, efficacy and gastric tolerability of P2026, a novel nitric oxide-releasing diclofenac in rat.

Authors:  Asif R Pathan; Manoj Karwa; Venu Pamidiboina; Jagannath J Deshattiwar; Nitin J Deshmukh; Parikshit P Gaikwad; Sunil V Mali; Dattatraya C Desai; Mini Dhiman; T Thanga Mariappan; Somesh D Sharma; Apparao Satyam; Kumar V S Nemmani
Journal:  Inflammopharmacology       Date:  2010-05-21       Impact factor: 4.473

Review 7.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Comparison of the antinociceptive activity of two new NO-releasing derivatives of the NSAID S-ketoprofen in rats.

Authors:  Gema Gaitan; F Javier Ahuir; Piero Del Soldato; Juan F Herrero
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

9.  Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.

Authors:  Anna Bratasz; Nathan M Weir; Narasimham L Parinandi; Jay L Zweier; Rajagopalan Sridhar; Louis J Ignarro; Periannan Kuppusamy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-23       Impact factor: 11.205

10.  Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin.

Authors:  M Mar Curros-Criado; Juan F Herrero
Journal:  Br J Pharmacol       Date:  2009-07-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.